This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medifast Weight-Control Center Opens In Bogota, Colombia

Stocks in this article: MED

OWINGS MILLS, Md., Dec. 9, 2013 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, announced today the opening of a Medifast Weight Control Center in Bogota, Colombia. 

(Logo: http://photos.prnewswire.com/prnh/20120613/NE24271LOGO-b)

The new Center in Bogota will open as a part of Medifast's strategic partnership with Medix, a leader in pharmaceutical obesity products.  The partnership provides Medifast the opportunity to expand distribution of its products throughout Mexico, Central America, and South America, through both retail centers and Medix's existing physician network.  Medix opened its first Medifast Weight Control Center in Mexico City in September, and this is the second of approximately 30 Centers Medix plans to open over the next several years.

" Colombia has a growing population seeking to lose weight and improve their overall health," said Michael MacDonald, Chairman and Chief Executive Officer, Medifast, Inc. "Together with Medix, we're proud to now be able to offer weight management options to support a healthier lifestyle."

More than 60 Medifast products have been approved by INVIMA, the Colombian regulatory commission, and several prominent Colombian physicians are ready to incorporate Medifast into their recommendations for clients and patients as needed.

"Medifast's scientific approach to weight management offers our clients a program that is safe and effective to help them reach and maintain their ideal weight," said Carlos Lopez Patan, Medix Chief Executive Officer.  "We are pleased to offer the Medifast program to our clients, and we look forward to much success."

Medifast products and programs have been recommended by more than 20,000 doctors since 1980. 

MED-G 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs